These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 8222093

  • 21. Comparison of the antithrombotic effect of PEG-hirudin and heparin in a human ex vivo model of arterial thrombosis.
    Bossavy JP, Sakariassen KS, Rübsamen K, Thalamas C, Boneu B, Cadroy Y.
    Arterioscler Thromb Vasc Biol; 1999 May; 19(5):1348-53. PubMed ID: 10323789
    [Abstract] [Full Text] [Related]

  • 22. Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-rich thrombus? Effects of recombinant hirudin, heparin, or aspirin.
    Mruk JS, Zoldhelyi P, Webster MW, Heras M, Grill DE, Holmes DR, Fuster V, Chesebro JH.
    Circulation; 1996 Feb 15; 93(4):792-9. PubMed ID: 8641009
    [Abstract] [Full Text] [Related]

  • 23. Markers of hemostatic system activation during thromboprophylaxis with recombinant hirudin in total hip replacement.
    Cofrancesco E, Cortellaro M, Leonardi P, Corradi A, Ravasi F, Bertocchi F.
    Thromb Haemost; 1996 Mar 15; 75(3):407-11. PubMed ID: 8701398
    [Abstract] [Full Text] [Related]

  • 24. Pharmacokinetics of recombinant hirudin in healthy horses.
    Feige K, Dennler M, Kästner SB, Wunderli-Allenspach H, Demuth D, Huber A.
    Equine Vet J; 2004 Mar 15; 36(2):135-41. PubMed ID: 15038436
    [Abstract] [Full Text] [Related]

  • 25. Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty.
    Topol EJ, Bonan R, Jewitt D, Sigwart U, Kakkar VV, Rothman M, de Bono D, Ferguson J, Willerson JT, Strony J.
    Circulation; 1993 May 15; 87(5):1622-9. PubMed ID: 8491018
    [Abstract] [Full Text] [Related]

  • 26. Recombinant hirudin (HBW 023) produces stable anticoagulation unaffected by circadian variation in patients with thrombolysis for acute myocardial infarction.
    Zeymer U, Mateblowski M, Neuhaus KL.
    Eur Heart J; 1996 Dec 15; 17(12):1836-40. PubMed ID: 8960425
    [Abstract] [Full Text] [Related]

  • 27. [Subcutaneous recombinant hirudin in the treatment of deep venous thrombosis. A pharmacokinetic study].
    Schiele F, Vuillemenot A, Mouhat T, Kramarz P, Kieffer Y, Camez A, Bassand JP.
    Arch Mal Coeur Vaiss; 1995 Mar 15; 88(3):329-35. PubMed ID: 7487286
    [Abstract] [Full Text] [Related]

  • 28. Experimental studies on a recombinant hirudin, CGP 39393.
    Gray E, Watton J, Cesmeli S, Barrowcliffe TW, Thomas DP.
    Thromb Haemost; 1991 Apr 08; 65(4):355-9. PubMed ID: 2057916
    [Abstract] [Full Text] [Related]

  • 29. Initial experience with a direct antithrombin, Hirulog, in unstable angina. Anticoagulant, antithrombotic, and clinical effects.
    Lidón RM, Théroux P, Juneau M, Adelman B, Maraganore J.
    Circulation; 1993 Oct 08; 88(4 Pt 1):1495-501. PubMed ID: 8403297
    [Abstract] [Full Text] [Related]

  • 30. Monitoring of argatroban and lepirudin anticoagulation in critically ill patients by conventional laboratory parameters and rotational thromboelastometry - a prospectively controlled randomized double-blind clinical trial.
    Beiderlinden M, Werner P, Bahlmann A, Kemper J, Brezina T, Schäfer M, Görlinger K, Seidel H, Kienbaum P, Treschan TA.
    BMC Anesthesiol; 2018 Feb 09; 18(1):18. PubMed ID: 29426286
    [Abstract] [Full Text] [Related]

  • 31. Persistent thrombin generation in humans during specific thrombin inhibition with hirudin.
    Zoldhelyi P, Bichler J, Owen WG, Grill DE, Fuster V, Mruk JS, Chesebro JH.
    Circulation; 1994 Dec 09; 90(6):2671-8. PubMed ID: 7994807
    [Abstract] [Full Text] [Related]

  • 32. Distinct effects of recombinant desulfatohirudin (Revasc) and heparin on plasma levels of fibrinopeptide A and prothrombin fragment F1.2 in unstable angina. A multicenter trial.
    Rao AK, Sun L, Chesebro JH, Fuster V, Harrington RA, Schwartz D, Gallo P, Matos D, Topol EJ.
    Circulation; 1996 Nov 15; 94(10):2389-95. PubMed ID: 8921778
    [Abstract] [Full Text] [Related]

  • 33. Guidance of anticoagulation after intracoronary implantation of Palmaz-Schatz stents by monitoring prothrombin and prothrombin fragment 1 + 2.
    Haude M, Hafner G, Jablonka A, Rupprecht HJ, Prellwitz W, Meyer J, Erbel R.
    Am Heart J; 1995 Aug 15; 130(2):228-38. PubMed ID: 7631600
    [Abstract] [Full Text] [Related]

  • 34. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study.
    Greinacher A, Völpel H, Janssens U, Hach-Wunderle V, Kemkes-Matthes B, Eichler P, Mueller-Velten HG, Pötzsch B.
    Circulation; 1995 Aug 15; 99(1):73-80. PubMed ID: 9884382
    [Abstract] [Full Text] [Related]

  • 35. Hirudin versus heparin for anticoagulation in continuous renal replacement therapy.
    Vargas Hein O, von Heymann C, Lipps M, Ziemer S, Ronco C, Neumayer HH, Morgera S, Welte M, Kox WJ, Spies C.
    Intensive Care Med; 2001 Apr 15; 27(4):673-9. PubMed ID: 11403068
    [Abstract] [Full Text] [Related]

  • 36. Influence of piroxicam coadministration on pharmacodynamic parameters and the plasma concentration/effect relationship of recombinant hirudin (CGP 39393).
    Thürmann P, Harder S, Kirchmaier CM.
    Eur J Clin Pharmacol; 1995 Apr 15; 48(3-4):241-6. PubMed ID: 7589048
    [Abstract] [Full Text] [Related]

  • 37. Thrombin inhibition and intracoronary thrombus formation: effect of polyethylene glycol-coupled hirudin in the stenosed, locally injured canine coronary artery.
    Rübsamen K, Kirchengast M.
    Coron Artery Dis; 1998 Apr 15; 9(1):35-42. PubMed ID: 9589189
    [Abstract] [Full Text] [Related]

  • 38. Comparison of hirudin and heparin as adjuncts to streptokinase thrombolysis in a canine model of coronary thrombosis.
    Rigel DF, Olson RW, Lappe RW.
    Circ Res; 1993 May 15; 72(5):1091-102. PubMed ID: 8477521
    [Abstract] [Full Text] [Related]

  • 39. Additive effect of the combined administration of low molecular weight heparin and recombinant hirudin on thrombus growth in a rabbit jugular vein thrombosis model.
    Biemond BJ, Levi M, Nurmohamed MT, Büller HR, ten Cate JW.
    Thromb Haemost; 1994 Sep 15; 72(3):377-80. PubMed ID: 7855787
    [Abstract] [Full Text] [Related]

  • 40. Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK).
    Neuhaus KL, von Essen R, Tebbe U, Jessel A, Heinrichs H, Mäurer W, Döring W, Harmjanz D, Kötter V, Kalhammer E.
    Circulation; 1994 Oct 15; 90(4):1638-42. PubMed ID: 7923646
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.